“Currently, states are struggling with the lack of sound scientific research available in CBD and long-term health impacts, including those to children,” Pam Miles of the Virginia Department of Agriculture, said. She added that her department “is hopeful that FDA will begin to supply significant leadership as it related to CBD, including research related to its health impacts.”…Brenda Morris, representing the Florida Department of Agriculture and Consumer Services, talked about the “patchwork of laws” surrounding CBD and how that has fostered an environment where “anything is allowed.”
FDA reaction: Amy Abernethy, the FDA principal deputy commissioner who helped organize the public meeting, identified several themes that emerged during the talks.
In general, there is a need to “further clarify the regulatory framework to reduce confusion in the market,” to provide that clarification in timely manner, to collect data on CBD to ensure that the products are safe and to create labeling standards so consumers know what they’re getting.
The report, Impossible to escape: The need for stronger restrictions on the placement of alcohol marketing in Australia released by the Public Health Advocacy Institute of WA (PHAIWA) at Curtin University, found almost two-thirds of complaints made to the Alcohol Advertising Review Board (AARB) over the past seven years had raised concerns about the placement of alcohol marketing in Australia.
The report found that 760 of the total 1126 complaints were about where alcohol marketing was placed in the community. Of the 760 placement-related complaints, almost 40% raised concerns that the advertisements were placed where young people were likely to be exposed or with content that would appeal to them. The report highlights the need for governments to introduce stronger restrictions to better protect children and young people from exposure to alcohol marketing.
Campaigners say medicinal cannabis being used as ‘Trojan horse’ towards legalisation. Ireland is “sleepwalking” into the legalisation of cannabis on the back of a campaign of misinformation about the drug, according to doctors who have set up a new group to campaign against liberalisation.
Criticising the “one-sided debate” on cannabis, the doctors say society has “taken its eye off the ball” in relation to the harmful effects of the drug.
In their practice, they say they are treating ever-growing numbers of patients suffering a range of side effects from abusing the drug.
Abstract: The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F1mice. Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD (acute toxicity, 24 h) or with daily doses of 0, 61.5, 184.5, or 615 mg/kg for 10 days (sub-acute toxicity). These doses were the allometrically scaled mouse equivalent doses (MED) of the maximum recommended human maintenance dose of CBD in EPIDIOLEX®(20 mg/kg). In the acute study, significant increases in liver-to-body weight (LBW) ratios, plasma ALT, AST, and total bilirubin were observed for the 2460 mg/kg dose. In the sub-acute study, 75% of mice gavaged with 615 mg/kg developed a moribund condition between days three and four. As in the acute phase, 615 mg/kg CBD increased LBW ratios, ALT, AST, and total bilirubin. Hepatotoxicity gene expression arrays revealed that CBD differentially regulated more than 50 genes, many of which were linked to oxidative stress responses, lipid metabolism pathways and drug metabolizing enzymes.
In conclusion, CBD exhibited clear signs of hepatotoxicity, possibly of a cholestatic nature. The involvement of numerous pathways associated with lipid and xenobiotic metabolism raises serious concerns about potential drug interactions as well as the safety of CBD.